2024
Financial Toxicity Among Patients With Advanced Solid Tumors Participating in Early-Phase Clinical Trials.
Blanter J, Van Hyfte G, Ahmad M, Xu S, Hapanowicz O, Fazilov G, Lu A, Lucas N, Wu K, Shelton G, DeMerchant M, Lachowicz M, Kier M, Werner M, Eder J, Galsky M, Marron T, Smith C, LoRusso P, Hofstatter E, Doroshow D. Financial Toxicity Among Patients With Advanced Solid Tumors Participating in Early-Phase Clinical Trials. JCO Oncology Practice 2024, op2400293. PMID: 39661920, DOI: 10.1200/op.24.00293.Peer-Reviewed Original ResearchEarly-phase clinical trialsSolid tumorsClinical trialsAssociated with higher FTFinancial toxicityBarriers to clinical trial enrollmentAdvanced solid malignanciesAdvanced solid tumorsInverse association with ageBaseline to 2 monthsYale Cancer CenterCOST scoreClinical trial enrollmentProspective survey studySolid malignanciesNo significant differenceBaseline FTTime of consentNovel therapiesPrimary outcomeCancer CenterSurvey 1Trial enrollmentPatientsEarly-phase
2013
State of the Art in Imaging and Chemoprevention for High-Risk Patients
Hofstatter E, Andrejeva L, Chagpar A. State of the Art in Imaging and Chemoprevention for High-Risk Patients. Current Breast Cancer Reports 2013, 5: 125-133. DOI: 10.1007/s12609-013-0104-1.Peer-Reviewed Original ResearchBreast cancer preventionCancer preventionBreast cancerAccurate breast cancer risk assessmentAppropriate breast cancer screeningBreast cancer risk assessmentChemoprevention clinical trialsHigh-risk patientsBreast cancer screeningPromising new optionCancer risk assessmentCancer screeningClinical trialsPractical updatePatientsEarly detectionCancerPreventionNew optionsRiskRisk assessmentChemopreventionOptionsBreastClinicians